Polpharma European CDMO Partner & API Manufacturer since 1951 Polpharma European CDMO Partner & API Manufacturer since 1951

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"iNtRON Biotechnology","sponsor":"Basilea Pharmaceutica","pharmaFlowCategory":"D","amount":"$CHECK CHECK","upfrontCash":"Undisclosed","newsHeadline":"Basilea Announces Exclusive License and Option Agreement for Potential First-In-Class Clinical-Stage Antibacterial Agent","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"iNtRON Biotechnology","sponsor":"Basilea Pharmaceutica","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"iNtRON, Executes Evaluation License and Option Agreement for SAL200","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"iNtRON Biotechnology","sponsor":"Basilea Pharmaceutica","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Basilea Announces Exclusive License and Option Agreement for Potential First-in-class Clinical-Stage Antibacterial Agent","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"Approved","date":"October 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals for Tonabacase

    Menu

    Tonabacase

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              iNtRON Biotechnology

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Basilea Announces Exclusive License and Option Agreement for Potential First-In-Class Clinical-Stage Antibacterial Agent

              Details:

              Upon successful completion of the preclinical evaluation phase, Basilea will have the exclusive option to license LSVT-1701 (tonabacase) for further clinical development and commercialization.

              Lead Product(s): Tonabacase

              Therapeutic Area: Infections and Infectious Diseases Product Name: LSVT-1701

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Basilea Pharmaceutica

              Deal Size: $CHECK CHECK Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement October 31, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              iNtRON Biotechnology

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Basilea Announces Exclusive License and Option Agreement for Potential First-in-class Clinical-Stage Antibacterial Agent

              Details:

              Under the agreement, Basilea will investigate SAL200 (tonabacase), a potential first-in-class clinical-stage antibacterial of the endolysin class, against methicillin-resistant and methicillin-susceptible Staphylococcus aureus.

              Lead Product(s): Tonabacase

              Therapeutic Area: Infections and Infectious Diseases Product Name: SAL200

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Basilea Pharmaceutica

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement October 31, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              iNtRON Biotechnology

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              iNtRON, Executes Evaluation License and Option Agreement for SAL200

              Details:

              Under the agreement, iNtRON grants Basilea exclusive right for preclinical evaluation of the antibacterial bio-drug N-Rephasin SAL200 (tonabacase), a novel endolysin-based anti-staphylococcal drug formulated for injection.

              Lead Product(s): Tonabacase

              Therapeutic Area: Infections and Infectious Diseases Product Name: N-Rephasin SAL200

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Basilea Pharmaceutica

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement October 30, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Bora Pharmaceuticals- Making success more certain.
              AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
              Post Enquiry
              POST ENQUIRY